Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCULPTURE: Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque Psoriasis
jRCT2080221614Phase 3
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of secukinumab in plaque psoriasis, sponsored by Novartis.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080221614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221614.